SAN DIEGO, Feb. 6, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment AXIM® Biotechnologies, Inc. (OTC: AXIM) was featured on a CBS New York News segment about the Company's clinical trials for its CanChew Plus® cannabidiol (CBD) chewing gum for the treatment of patients with irritable bowel syndrome (IBS), a disease that affects up to 15% of the world population.
The segment includes an in-depth interview with CEO of AXIM® Biotechnologies Dr. George E. Anastassov, MD, DDS, MBA about the functionality of CanChew Plus® and AXIM® CTO Lekhram Changoer about how the double-blind, placebo-controlled trial is being conducted at Wageningen University in the Netherlands. In addition, the report interviews a CanChew® customer who gives testimony to the product's positive effects for gout and IBS.
"It's motivating to see national news coverage on AXIM, a company that is making an impact on the well-being of individuals through products that treat conditions for which there is currently no effective remedy," said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. "This trial is definitely newsworthy, as it's the first advancement in cannabinoid research for treatment of IBS in medical history. We're excited to see AXIM continually reaching milestones in its clinical development program."
IBS is the most common disorder diagnosed by gastroenterologists and accounts for up to 12% of total visits to primary care providers, accounting for between 2.4 – 3.5 million annual physician visits in the United States alone.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
AXIM® Biotechnologies, Inc. (OTC: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com.
About CanChew® and CanChew Plus®
CanChew® is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew® website include:
- Non-habit forming
- No prescription needed
- Available in all 50 states
- Great-tasting mint gum has no artificial sweeteners or preservatives
- Non-GMO, gluten free, vegan and kosher
CanChew Plus® is a vastly improved delivery system than the alpha version of CanChew® Gum. It is produced by a leading European functional gum manufacturer.
Featured in Healthy Living Magazine, CanChew® was also recognized by the HealthyLiving Foundation and honored with its Triple Leaf Award.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cbs-new-york-features-medical-marijuana-inc-investment-axim-biotechs-flagship-cbd-chewing-gum-ibs-clinical-trial-300402380.html
SOURCE Medical Marijuana, Inc.